Pages that link to "Q35013389"
Jump to navigation
Jump to search
The following pages link to Sildenafil influences lower urinary tract symptoms. (Q35013389):
Displaying 50 items.
- Korean clinical practice guideline for benign prostatic hyperplasia (Q26766302) (← links)
- Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update (Q26775925) (← links)
- Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction (Q27011502) (← links)
- The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors (Q27025700) (← links)
- Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment (Q33289952) (← links)
- Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review (Q33706631) (← links)
- Influence of sildenafil on blood oxygen saturation of the obstructed bladder (Q33767906) (← links)
- Combination therapy for erectile dysfunction: an update review (Q33851191) (← links)
- The Effect of Transurethral Resection of the Prostate on Erectile Function in Patients with Benign Prostatic Hyperplasia (Q34075988) (← links)
- Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options (Q34114694) (← links)
- Recent advances in management of bladder overactivity (Q34167658) (← links)
- Prospective pharmacologic therapies for the overactive bladder (Q35076367) (← links)
- Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). (Q35089850) (← links)
- Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction (Q35183603) (← links)
- Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life (Q35203797) (← links)
- Drugs and future candidates (Q35347721) (← links)
- Sildenafil: A 4-year update in the treatment of 20 million erectile dysfunction patients (Q35586247) (← links)
- Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. (Q35637347) (← links)
- The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence (Q35839581) (← links)
- The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (Q35993920) (← links)
- Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway? (Q36206614) (← links)
- Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. (Q36292421) (← links)
- Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP? (Q36311552) (← links)
- Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate (Q36360868) (← links)
- Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice (Q36371582) (← links)
- Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? (Q36409148) (← links)
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms (Q36579735) (← links)
- Potential future options in the pharmacotherapy of female sexual dysfunction (Q36626775) (← links)
- Correlation between risk factors for vascular disease and the American Urological Association Symptom Score (Q36709646) (← links)
- Lower urinary-tract symptoms and testosterone in elderly men (Q36839032) (← links)
- A survey of commonalities relevant to function and dysfunction in pelvic and sexual organs (Q36918641) (← links)
- Phosphodiesterase type 5 inhibitors: state of the therapeutic class (Q36993658) (← links)
- Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence (Q37018954) (← links)
- PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. (Q37025381) (← links)
- Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. (Q37038183) (← links)
- Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction (Q37058005) (← links)
- The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms (Q37209592) (← links)
- PDE5 inhibitors for LUTS. (Q37581408) (← links)
- Microvascular complications in diabetic erectile dysfunction: do we need other alternatives? (Q37624310) (← links)
- Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction (Q37719924) (← links)
- The medical treatment of overactive bladder, including current and future treatments. (Q37836943) (← links)
- Update on the sexual impact of treatment for benign prostatic hyperplasia (Q38052091) (← links)
- Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms (Q38079523) (← links)
- Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. (Q38093143) (← links)
- The role of phosphodiesterases in bladder pathophysiology (Q38106628) (← links)
- The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (Q38153654) (← links)
- Non-Hormonal treatment of BPH/BOO (Q38205423) (← links)
- Neural control of lower urinary tract and targets for pharmacological therapy (Q38227058) (← links)
- Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors (Q38815890) (← links)
- Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm (Q38913912) (← links)